673P A prospective comparative study on biweekly docetaxel, cisplatin, 5-fluorouracil, leucovorin (TPFL) versus triweekly TPF as an induction chemotherapy in locally advanced squamous cell carcinoma of head and neck

S Anantharamu,L.A Jacob,S.C Saldanha,L Dasappa,M.C Suresh Babu,A.H Rudresha,K.N Lokesh,R Lakkavalli Krishnappa

doi:10.1016/j.annonc.2022.07.797

673P A prospective comparative study on biweekly docetaxel, cisplatin, 5-fluorouracil, leucovorin (TPFL) versus triweekly TPF as an induction chemotherapy in locally advanced squamous cell carcinoma of head and neck

S Anantharamu, L.A Jacob + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.797

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: Kidwai Memorial Institute of Oncology

#Squamous Cell Carcinoma Of Head #Squamous Cell Carcinoma Of Head And Neck + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Induction chemotherapy (ICT) is widely used in locally advanced squamous cell carcinoma of head and neck (SCCHN). Triweekly TPF (Docetaxel/Cisplatin/5FU) is most commonly used regimen but is associated with significant neutropenia. Hence, we conducted a phase II randomised prospective study to see if biweekly TPF regimen was associated with equal response rates with lesser toxicities in our setting.

Full Text